Protalix BioTherapeutics (PLX) Cash & Current Investments (2010 - 2026)

Protalix BioTherapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 68.93% year-over-year to $10.8 million in Q1 2026; TTM through Mar 2026 was $10.8 million, a 68.93% decrease from a year earlier, with the FY2025 full-year figure at $16.3 million, down 53.22% from the prior year.
• Cash & Current Investments eased to $10.8 million in Q1 2026 per PLX's latest filing, from $16.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $48.5 million in Q1 2024 and bottomed at $10.8 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $33.0 million (2023), against an average of $32.4 million.
• Across the five-year window, Cash & Current Investments soared 100.9% in 2023 and sank 68.93% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $22.2 million in 2022, then surged by 100.9% to $44.6 million in 2023, then dropped by 21.84% to $34.8 million in 2024, then slumped by 53.22% to $16.3 million in 2025, then sank by 33.76% to $10.8 million in 2026.
• Per Business Quant, the three latest PLX Cash & Current Investments figures stand at $10.8 million (Q1 2026), $16.3 million (Q4 2025), and $29.4 million (Q3 2025).